Company news: Time, Takeda, Amylin, PwC

Share this article:

Time Inc. has rebranded its targeted marketing division as Targeted Media Health and refocused it exclusively on pharma and other healthcare advertisers. In addition to leveraging the company's magazine portfolio, the division offers OTC and wellness brands “educational and health-related content delivered directly to consumers at multiple touch points,” from online to point-of-care, the company said. “Adding targeted digital and mobile offerings, as well as an in-home magazine component, makes Targeted Media Health a one-stop solution for fulfilling the dimensional elements of any pharmaceutical brand initiative,” said VP managing director John Kenyon.

Takeda and Amylin dissolved their three-year-old collaboration to develop compounds for the treatment of obesity. The move follows the August 2011 discontinuation of work on the partnership's lead candidate, pramlintide/metreleptin, which was in Phase II clinical trials for use as a twice-a-day injection.

PricewaterhouseCoopers' Health Research Institute is fielding a regulatory analysis team. The three-person team “tracks and analyzes legislative and regulatory issues across the US health landscape, delivering timely business insights to help executive decision makers navigate rapid change,” and includes former Teva director of regulatory affairs Bobby Clark and journalist Matt DoBias of Modern Healthcare and other publications. 

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.